Cardiopulmonary Function and Age-Related Decline Across the Breast Cancer Survivorship Continuum
Cardiopulmonary Function and Age-Related Decline Across the Breast Cancer Survivorship Continuum
复制标题
DOI：
10.1200/jco.2011.39.9014
复制
发表时间：
2012-07-10
影响因子：
45.3
通讯作者：
Haykowsky, Mark
中科院分区：
文献类型：
--
作者：
Jones, Lee W.;Courneya, Kerry S.;Haykowsky, Mark
PurposeTo评估心肺功能（以峰值耗氧量[VO 2 peak]测量）在乳腺癌的连续性和其预后意义的妇女与metastatic disease.Patients和MethodsPatients乳腺癌代表四个横截面cohort，即（1）前，（2）期间，（3）后辅助治疗非转移性疾病，（4）在治疗转移性疾病进行了研究。采用心肺运动试验（CPET）和呼气分析评估VO 2峰值。使用考克斯比例风险模型根据VO 2峰值类别（= 15.4 mL）估计死亡风险< 15.4 v >。kg（-1）。min（-1））与调整临床factors.ResultsA共248名妇女（年龄，55 +/- 8岁）完成了CPET。平均VO 2峰值为17.8 +/-，标准差为4.3 mL。kg（-1）。min（-1），相当于比年龄匹配的健康久坐女性低27% +/- 17%。对于整个队列，32%的VO 2峰值小于15.4 mL。kg（-1）。min（-1）-功能独立性所需的VO 2峰值。VO 2峰值在乳腺癌队列中的相对（mL）显著不同。kg（-1）。min（-1））和绝对值（L . min（-1））VO 2 peak（分别为P = 0.017和P <0.001）; VO 2 peak在有转移性疾病的女性中最低。转移性疾病患者（n = 52）与达到VO 2峰值的患者相比
PurposeTo evaluate cardiopulmonary function (as measured by peak oxygen consumption [VO2peak]) across the breast cancer continuum and its prognostic significance in women with metastatic disease.Patients and MethodsPatients with breast cancer representing four cross-sectional cohorts-that is, (1) before, (2) during, and (3) after adjuvant therapy for nonmetastatic disease, and (4) during therapy in metastatic disease-were studied. A cardiopulmonary exercise test (CPET) with expired gas analysis was used to assess VO2peak. A Cox proportional hazards model was used to estimate the risk of death according to VO2peak category (< 15.4 v >= 15.4 mL . kg(-1) . min(-1)) with adjustment for clinical factors.ResultsA total of 248 women (age, 55 +/- 8 years) completed a CPET. Mean VO2peak was 17.8 +/- a standard deviation of 4.3 mL . kg(-1) . min(-1), the equivalent of 27% +/- 17% below age-matched healthy sedentary women. For the entire cohort, 32% had a VO2peak less than 15.4 mL . kg(-1) . min(-1)-the VO2peak required for functional independence. VO2peak was significantly different across breast cancer cohorts for relative (mL . kg(-1) . min(-1)) and absolute (L . min(-1)) VO2peak (P = .017 and P < .001, respectively); VO2peak was lowest in women with metastatic disease. In patients with metastatic disease (n = 52), compared with patients achieving a VO2peak